| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2013-07-04 18:56:32 UTC |
|---|
| Update Date | 2019-07-23 07:14:59 UTC |
|---|
| HMDB ID | HMDB0060743 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 3-Hydroxynevirapine glucuronide |
|---|
| Description | 3-Hydroxynevirapine glucuronide is a metabolite of nevirapine. Nevirapine, also marketed under the trade name Viramune, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. As with other antiretroviral drugs, HIV rapidly develops resistance if nevirapine is used alone, so recommended therapy consists of combinations of three or more antiretrovirals. (Wikipedia) |
|---|
| Structure | CC1=C2N=C(OC3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1O InChI=1S/C21H22N4O8/c1-8-11(26)7-23-18-12(8)24-19(10-3-2-6-22-17(10)25(18)9-4-5-9)33-21-15(29)13(27)14(28)16(32-21)20(30)31/h2-3,6-7,9,13-16,21,26-29H,4-5H2,1H3,(H,30,31)/t13-,14-,15+,16-,21?/m0/s1 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C21H22N4O8 |
|---|
| Average Molecular Weight | 458.4214 |
|---|
| Monoisotopic Molecular Weight | 458.1437637 |
|---|
| IUPAC Name | (2S,3S,4S,5R)-6-({2-cyclopropyl-6-hydroxy-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaen-10-yl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| Traditional Name | (2S,3S,4S,5R)-6-({2-cyclopropyl-6-hydroxy-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaen-10-yl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC1=C2N=C(OC3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1O |
|---|
| InChI Identifier | InChI=1S/C21H22N4O8/c1-8-11(26)7-23-18-12(8)24-19(10-3-2-6-22-17(10)25(18)9-4-5-9)33-21-15(29)13(27)14(28)16(32-21)20(30)31/h2-3,6-7,9,13-16,21,26-29H,4-5H2,1H3,(H,30,31)/t13-,14-,15+,16-,21?/m0/s1 |
|---|
| InChI Key | GDAAYOYNGMRKSI-IQSUWLOCSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as o-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through an O-glycosidic bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbohydrates and carbohydrate conjugates |
|---|
| Direct Parent | O-glucuronides |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1-o-glucuronide
- O-glucuronide
- Hexose monosaccharide
- Alkyldiarylamine
- Glycosyl compound
- O-glycosyl compound
- Pyrido-para-diazepine
- Beta-hydroxy acid
- Methylpyridine
- Hydroxypyridine
- Hydroxy acid
- Monosaccharide
- Oxane
- Pyran
- Pyridine
- Imidolactone
- Imidolactam
- Heteroaromatic compound
- Secondary alcohol
- Organoheterocyclic compound
- Carboxylic acid
- Carboxylic acid derivative
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Azacycle
- Acetal
- Monocarboxylic acid or derivatives
- Polyol
- Oxacycle
- Organopnictogen compound
- Alcohol
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxide
- Organonitrogen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.26 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.1637 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.37 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1223.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 182.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 102.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 145.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 63.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 332.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 449.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 168.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 695.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 104.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1329.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 223.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 282.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 433.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 134.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 234.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 3-Hydroxynevirapine glucuronide,1TMS,isomer #1 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3811.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TMS,isomer #2 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3818.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TMS,isomer #3 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3823.6 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3779.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TMS,isomer #5 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3820.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #1 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3707.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #10 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3714.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #2 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3720.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #3 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3715.5 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3724.5 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #5 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3720.1 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #6 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3707.4 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #7 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3734.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #8 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3715.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TMS,isomer #9 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3713.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #1 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3700.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #10 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3703.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #2 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3680.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #3 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3687.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3690.4 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #5 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3694.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #6 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3696.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #7 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3688.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #8 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3703.6 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TMS,isomer #9 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3692.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,4TMS,isomer #1 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3694.6 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,4TMS,isomer #2 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3699.4 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,4TMS,isomer #3 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3698.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,4TMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3705.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,4TMS,isomer #5 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3705.5 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,5TMS,isomer #1 | CC1=C(O[Si](C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C)C1=CC=CN=C1N2C1CC1 | 3729.0 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TBDMS,isomer #1 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3981.0 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TBDMS,isomer #2 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3988.1 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TBDMS,isomer #3 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 3999.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TBDMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 3987.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,1TBDMS,isomer #5 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4004.4 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #1 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4027.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #10 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4039.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #2 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4043.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #3 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4006.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4025.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #5 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4038.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #6 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4026.0 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #7 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4035.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #8 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4044.4 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,2TBDMS,isomer #9 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4050.1 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #1 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4121.3 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #10 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4138.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #2 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4091.8 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #3 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4107.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #4 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4096.2 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #5 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4117.9 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #6 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4111.1 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #7 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O)C1=CC=CN=C1N2C1CC1 | 4109.1 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #8 | CC1=C(O[Si](C)(C)C(C)(C)C)C=NC2=C1N=C(OC1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4121.7 | Semi standard non polar | 33892256 | | 3-Hydroxynevirapine glucuronide,3TBDMS,isomer #9 | CC1=C(O)C=NC2=C1N=C(OC1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C)C1=CC=CN=C1N2C1CC1 | 4112.0 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - 3-Hydroxynevirapine glucuronide GC-MS (Non-derivatized) - 70eV, Positive | splash10-06r6-9317400000-2486a8005a174aa31d9c | 2017-09-20 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 3-Hydroxynevirapine glucuronide GC-MS (3 TMS) - 70eV, Positive | splash10-0a4r-6614149000-bdd1a5d57eb2510cbf83 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 3-Hydroxynevirapine glucuronide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 10V, Positive-QTOF | splash10-052f-0040900000-eac92ad12a89af325070 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 20V, Positive-QTOF | splash10-00lr-0190000000-b1c04c610709f115b3a6 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 40V, Positive-QTOF | splash10-016u-4190000000-8f19cc71fca2b4d1d15e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 10V, Negative-QTOF | splash10-0bt9-1220900000-79e85e6a466fdfa81581 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 20V, Negative-QTOF | splash10-0040-7724900000-5ba110269c9e13ba9a3c | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 40V, Negative-QTOF | splash10-001l-7491000000-2b21884c17147ef12b8a | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 10V, Positive-QTOF | splash10-06r6-0200900000-392527fcbc53c24997d5 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 20V, Positive-QTOF | splash10-053u-0138900000-e1edc6b7ef0b0839f035 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 40V, Positive-QTOF | splash10-000x-1391000000-969715dedf14da6e7cb7 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 10V, Negative-QTOF | splash10-0a4i-0010900000-92d9d6816c3293890bc0 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 20V, Negative-QTOF | splash10-0540-1192400000-9809461a6cc5cd3e2d26 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 3-Hydroxynevirapine glucuronide 40V, Negative-QTOF | splash10-000i-1090000000-66404caf8df43c572ef9 | 2021-10-12 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|